Movatterモバイル変換


[0]ホーム

URL:


US2981641A - Tobacco products - Google Patents

Tobacco products
Download PDF

Info

Publication number
US2981641A
US2981641AUS3718AUS371860AUS2981641AUS 2981641 AUS2981641 AUS 2981641AUS 3718 AUS3718 AUS 3718AUS 371860 AUS371860 AUS 371860AUS 2981641 AUS2981641 AUS 2981641A
Authority
US
United States
Prior art keywords
tobacco
nicotine
nornicotine
salt
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US3718A
Inventor
Robert C O'neill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stauffer Chemical Co
Original Assignee
Stauffer Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stauffer Chemical CofiledCriticalStauffer Chemical Co
Priority to US3718ApriorityCriticalpatent/US2981641A/en
Application grantedgrantedCritical
Publication of US2981641ApublicationCriticalpatent/US2981641A/en
Anticipated expirationlegal-statusCritical
Expired - Lifetimelegal-statusCriticalCurrent

Links

Classifications

Definitions

Landscapes

Description

TOBACCO PRODUCTS Robert C. ONeill, New York, N.Y., assignor to Stauifer Chemical Company, New York, N.Y., a corporation of Delaware No Drawing. Filed Jan. 21, 1960, Ser. No. 3,718
7 Claims. (Cl. 131-17) The present invention is concerned with treated tobacco products. In particular, it deals with tobacco in which there has been incorporated a compound which is an antagonist for nicotine and which has a particular chemical structure.
The compounds useful in the present invention as antagonists for nicotine are chemically related to nicotine itself,- but they differ from nicotine in that the methyl group present on the nitrogen atom in the -membered ring of nicotine has been replaced by a lower alkyl group containing from 2 to 8 carbon atoms. As examples of suitable alkyl groups there may be mentioned the ethyl group, the propyl group, the isopropyl group, the hexyl group, the isobutyl group, the octyl group and the allyl group.
The antagonist may be used in the form of a free base, but it is preferred to use it in the form of a salt of an acid. It is most preferred to use the antagonist as the salt of an organic acid, particularly an organic acid which naturally forms salts with nicotine in tobacco, e.g. citric acid and malic acid.
Many persons who smoke desire to break the smoking habit. The reasons for desiring to break the habit are many and varied, and may be based on advice from a physician or purely on economic considerations. In any case it has been the experience of numerous smokers, and particularly of very heavy smokers, that it is very difficult to give up the tobacco habit.
The compositions of the present invention are useful in assisting a smoker to break the tobacco habit. Tobaccos treated in accordance with the present invention, when burned in accordance with usual smoking practice, yield a smoke which contains vapors of the compound which is antagonistic to nicotine. The smoke provides the desired aroma and taste of smoke from conventional tobacco, but because of the antagonistic action of the additives, the physiological responses elicited by nicotine and related alkaloids naturally in tobacco are diminished. This diminished physiological response helps the smoker to stop smoking or to reduce the smoking habit.
In accordance with the present invention the nicotine antagonist, which is in all cases a tertiary amine, is incorporated in the tobacco, preferably in the form of a salt with an organic acid with naturally occurs with nicotine in tobacco, for example citric and malic acids. A solution of the salt is sprayed on the tobacco prior to the final processing steps in which it is made into the usual forms such as cigarettes, cigars and pipe tobacco. The amount of antagonist to be incorporated in the tobacco is preferably of the same order of magnitude as the amount of nicotine present in the tobacco. Information pnblished in the scientific literature indicates that the amount of nicotine present in tobacco varies from 0.5 to 8.0%. In the case of cigarette tobacco, the usual range is from 0.7 to 3.0%, with about 1.5% being an average value.
United ntates Patent The N-alkyl nornicotine compounds of the present invention are prepared by the reaction of nornicotine, which occurs naturally in tobacco, and the appropriate alkyl halide. The acid addition salts are prepared by simple reaction between the free base and an acid, for example, acetic acid, hydrochloric acid, sulfuric acid, phosphoric acid, citric acid and malic acid.
The following examples are given solely for the purposes of illustration and are not to be considered limitations of the invention, many variations of which will occur to those skilled in the art without departing from the spirit or scope thereof.
Example 1 Tobacco leaves are sprayed with an aqueous solution of the citrate salt of N-allyl nornicotine, so that after drying, the tobacco contains 3% of the added material. The spraying operation is conducted so that the additive is uniformly distributed throughout the tobacco mass. The tobacco is then processed in the normal fashion, and made into cigarettes, cigars or pipe tobacco as desired.
Smokers who substitute tobacco treated in accordance with the present invention for their normal conventional cigars, pipes or cigarettes experience the same desirable taste as with conventional tobacco, but also experience a decrease in the craving for tobacco. The subjects find that less will power is required in order to decrease or completely eliminate the smoking habit.
Example 2 The procedure of Example 1 may be repeated except that in place of the citrate salt, the malic acid salt is used. In like manner, when in place of N-allyl nornicotine, N-ethyl nornicotine, Nhexyl nornicotine or N-octyl nornicotine is used, either in the form of the free base or an acid addition salt, similar results are obtained. The concentration of the additive may be varied from 0.5 to 8.0%.
What is claimed is:
1. As a novel composition of matter, tobacco comprising from 0.5 to 8.0% of a compound selected from the group consisting of N-alkyl nornicotine compounds containing from 2 to 8 carbon atoms in the alkyl group, and acid addition salts thereof.
2. As a novel composition of matter, tobacco comprising from 0.5 to 8.0% of an N-alkyl nornicotine compound containing from 2 to 8 carbon atoms in the alkyl group, said compound being present in the form of a salt of an organic acid which naturally forms a salt with nicotine in tobacco.
3. As a novel composition of matter, tobacco comprising from 0.5 to 8.0% of N-allyl nornicotine in the form of a salt of an organic acid which naturally forms a salt with nicotine in tobacco.
4. As a novel composition of matter, tobacco comprising from 0.7 to 3.0% of an N-alkyl nornicotine compound containing from 2 to 8 carbon atoms in the alkyl group, said compound being present in the form of a salt of an organic acid which naturally forms a salt with nicotine in tobacco.
5. As a novel composition of matter, tobacco comprising from 0.7 to 3.0% of N-allyl nornicotine in the form of a salt of an organic acid which naturally'forms a salt with nicotine in tobacco.
6. As a novel composition of matter, tobacco comprising from 0.5 to 8.0% of N-allyl nornicotine citrate.
7. As a novel composition of matter, tobacco comprising from 0.7 to 3.0% of N-allyl nornicotine citrate.
No references cited.

Claims (1)

1. AS A NOVEL COMPOSITION OF MATTER, TOBACCO COMPRISING FROM 0.5 TO 8.0% OF A COMPOUND SELECTED FROM THE GROUP CONSISTING OF N-ALKYL NORNICOTINE COMPOUNDS CONTAINING FROM 2 TO 8 CARBON ATOMS IN THE ALKYL GROUP, AND ACID ADDITION SALTS THEREOF.
US3718A1960-01-211960-01-21Tobacco productsExpired - LifetimeUS2981641A (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
US3718AUS2981641A (en)1960-01-211960-01-21Tobacco products

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
US3718AUS2981641A (en)1960-01-211960-01-21Tobacco products

Publications (1)

Publication NumberPublication Date
US2981641Atrue US2981641A (en)1961-04-25

Family

ID=21707244

Family Applications (1)

Application NumberTitlePriority DateFiling Date
US3718AExpired - LifetimeUS2981641A (en)1960-01-211960-01-21Tobacco products

Country Status (1)

CountryLink
US (1)US2981641A (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3071509A (en)*1961-03-091963-01-01Stauffer Chemical CoN-alkyl-nornicotine:nicotine antagonist
US4765348A (en)*1986-12-121988-08-23Brown & Williamson Tobacco CorporationNon-combustible simulated cigarette device
US5316759A (en)*1986-03-171994-05-31Robert J. SchaapAgonist-antagonist combination to reduce the use of nicotine and other drugs
WO1996027303A1 (en)*1995-03-061996-09-12Lectec CorporationNicotine-free smoking material
US5596007A (en)*1992-05-181997-01-21Pharmaco Behavioral Associates, Inc.Therapeutic method to alleviate the craving associated with cessation of tobacco with cotinine
US5612357A (en)*1992-05-181997-03-18Pharmaco Behavioral Associates, Inc.Use of cotinine to assist in the cessation of tobacco smoking
US20080233197A1 (en)*2006-06-192008-09-25Francis Joseph MatthewsPharmaceutical compositions
US20100151014A1 (en)*2008-12-162010-06-17Alpharma Pharmaceuticals, LlcPharmaceutical composition
US20100152221A1 (en)*2007-12-172010-06-17Alpharma Pharmaceuticals, LlcPharmaceutical composition
US20100266645A1 (en)*2007-12-172010-10-21Alfred LiangPharmaceutical compositions
US20110014280A1 (en)*2002-09-202011-01-20Garth BoehmSequestering subunit and related compositions and methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None*

Cited By (25)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3071509A (en)*1961-03-091963-01-01Stauffer Chemical CoN-alkyl-nornicotine:nicotine antagonist
US5316759A (en)*1986-03-171994-05-31Robert J. SchaapAgonist-antagonist combination to reduce the use of nicotine and other drugs
US5574052A (en)*1986-03-171996-11-12Robert J. SchaapAgonist-antagonist combination to reduce the use of nicotine and other drugs
US5935975A (en)*1986-03-171999-08-10Robert J. SchaapAgonist-antagonist combination to reduce the use of nicotine and other drugs
US4765348A (en)*1986-12-121988-08-23Brown & Williamson Tobacco CorporationNon-combustible simulated cigarette device
US5596007A (en)*1992-05-181997-01-21Pharmaco Behavioral Associates, Inc.Therapeutic method to alleviate the craving associated with cessation of tobacco with cotinine
US5612357A (en)*1992-05-181997-03-18Pharmaco Behavioral Associates, Inc.Use of cotinine to assist in the cessation of tobacco smoking
WO1996027303A1 (en)*1995-03-061996-09-12Lectec CorporationNicotine-free smoking material
US5880164A (en)*1995-03-061999-03-09Lectec CorporationNicotine-free smoking material
US20110027455A1 (en)*2002-09-202011-02-03Garth BoehmSequestering subunit and related compositions and methods
US20110014280A1 (en)*2002-09-202011-01-20Garth BoehmSequestering subunit and related compositions and methods
US8685443B2 (en)2002-09-202014-04-01Alpharma Pharmaceuticals LlcSequestering subunit and related compositions and methods
US8685444B2 (en)2002-09-202014-04-01Alpharma Pharmaceuticals LlcSequestering subunit and related compositions and methods
US8158156B2 (en)2006-06-192012-04-17Alpharma Pharmaceuticals, LlcAbuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US20100143483A1 (en)*2006-06-192010-06-10Alpharma Pharmaceuticals, Llc.Pharmaceutical compositions
US20080233197A1 (en)*2006-06-192008-09-25Francis Joseph MatthewsPharmaceutical compositions
US20090162450A1 (en)*2006-06-192009-06-25Alpharma Pharmaceuticals, Llc.Pharmaceutical composition
US7682634B2 (en)2006-06-192010-03-23Alpharma Pharmaceuticals, LlcPharmaceutical compositions
US7682633B2 (en)2006-06-192010-03-23Alpharma Pharmaceuticals, LlcPharmaceutical composition
US8846104B2 (en)2006-06-192014-09-30Alpharma Pharmaceuticals LlcPharmaceutical compositions for the deterrence and/or prevention of abuse
US8877247B2 (en)2006-06-192014-11-04Alpharma Pharmaceuticals LlcAbuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US20100152221A1 (en)*2007-12-172010-06-17Alpharma Pharmaceuticals, LlcPharmaceutical composition
US20100266645A1 (en)*2007-12-172010-10-21Alfred LiangPharmaceutical compositions
US8623418B2 (en)2007-12-172014-01-07Alpharma Pharmaceuticals LlcPharmaceutical composition
US20100151014A1 (en)*2008-12-162010-06-17Alpharma Pharmaceuticals, LlcPharmaceutical composition

Similar Documents

PublicationPublication DateTitle
US2981641A (en)Tobacco products
DE1517311A1 (en) Method and means for incorporating flavors into tobacco
WO1987006104A1 (en)Improvements in and relating to tobacco products
EP0052969A3 (en)Flavorant compounds, their pyrolysis products, and smoking and food compositions containing them
DE2356706A1 (en) SMOKE MIXTURES
DE1692759B2 (en) Flavored tobacco
ATE7260T1 (en) FLAVORING COMPOSITION FOR TOBACCO, PROCESS FOR PRODUCTION THEREOF AND TOBACCO PRODUCT CONTAINING SUCH COMPOSITION.
US3071509A (en)N-alkyl-nornicotine:nicotine antagonist
US3136319A (en)Smoking tobacco product having menthyl keto ester additive
US3890981A (en)Novel process for altering the organoleptic properties of tobacco using one or more alpha-pyrones and process
US3782391A (en){62 -methylvaleric acid alkyl esters as tobacco flavorants
US3126012A (en)Smqeong tobacco additives in the form
US3128772A (en)Smoking tobacco additives in the form of menthyl ethers
EP0008299A1 (en) POLY (ISOPROPENYL ESTER) AS A CARBOXYL ACID RELEASING AGENT IN TOBACCO.
US3334637A (en)Smoking product having flavorant additive
US3112755A (en)Tobacco product
US4183362A (en)Decreasing the burn rate of smoking tobaccos
US3217716A (en)Tobacco composition
US2872360A (en)Tobacco
US2985549A (en)Low toxicity tobacco
US2733174A (en)Compositions containing monosodium
US3280824A (en)Tobacco
JP2763637B2 (en) Oxo-ionol carbonate useful as a tobacco flavor
US2978365A (en)Tobacco
US3381690A (en)Tobacco product

[8]ページ先頭

©2009-2025 Movatter.jp